AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.91
-0.01 (-1.39%)
▼
5d:
+3.87%
30d:
-25.69%
90d:
-11.12%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.91, which is considered oversold relative to its 30-day fair value range of $0.93 to $1.35. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.8) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.95.
Market Sentiment: AKBA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.80 (+319.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.95.
Market Sentiment: AKBA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.80 (+319.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.93 -
$1.35
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (88/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 319.1% below Wall St target ($3.80)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$0.93 -
$1.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.81
Resistance Level
$0.96
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.75
Wall Street Target
$3.80
(+319.1%)
Revenue Growth (YoY)
-21.4%
Profit Margin
-13.5%
PE vs Historical
-2.8 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 8:17 AM ET
Data refreshes hourly during market hours. Next update: 9:17 AM
Data refreshes hourly during market hours. Next update: 9:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
